We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00961025
Recruitment Status : Unknown
Verified August 2009 by Dong-A ST Co., Ltd..
Recruitment status was:  Recruiting
First Posted : August 18, 2009
Last Update Posted : August 24, 2009
Information provided by:

Study Description
Brief Summary:
This is a dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation study. The study is designed to describe the relationship between multiple doses and pharmacokinetic/pharmacodynamic parameters of DA-1229 as well as safety profile.

Condition or disease Intervention/treatment Phase
Diabetes Mellitis Type 2 Drug: DA-1229 Drug: Placebo Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 110 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose Escalation Clinical Phase 1 Study to Investigate the Safety, Tolerance, and Pharmacokinetics/Pharmacodynamics of DA-1229 in Healthy Male Subjects
Study Start Date : May 2009
Estimated Primary Completion Date : February 2010
Estimated Study Completion Date : March 2010
Arms and Interventions

Arm Intervention/treatment
Placebo Comparator: Placebo Drug: Placebo
Experimental: DA-1229
Drug: DA-1229

single dose study : DA-1229 1.25,2.5,5,10,20,40,60mg

multiple dose study : DA-1229 5,10,20,40mg

Outcome Measures

Primary Outcome Measures :
  1. To characterize the pharmacokinetic/pharmacodynamic of DA-1229 in healthy male subjects [ Time Frame: Multiple blood and urine samples will be collected for 120 hours after dosing of DA-1229 ]

Secondary Outcome Measures :
  1. To evaluate the safety and tolerance of DA-1229 [ Time Frame: up to 10 days (single dose study), 17 days (single dose study for food effect), 20 days (multiple dose study) ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 20-45 years healthy male subjects
  • Body weight :50-90kg, BMI between 18.5-25
  • Blood glucose level of 70-110mg/dL on the FPG test

Exclusion Criteria:

  • have a family history of diabetes
  • Serum AST(SGOT), ALT(SGPT)>1.25 times upper limit of normal
  • Creatinine clearance rate<80mL/min
  • show SBP =<100mmHg or >=150mmHg, or DBP=<65mmHg or >=95mmHg, or tachycardia (PR>=100times/min)
  • have a history of drug abuse or show positive for drug abuse or cotinine at urine screening
  • smokers
  • can not digest high-fat or high-calorie food(applicable only for the 10mg dose group subjects
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00961025

Contact: Kyung-Sang Yu, M.D., Ph.d., M.B.A. +82-2-2072-1920 ksyu@snuh.ac.kr

Korea, Republic of
Clinical Trials Center, Seoul National University Hospital Recruiting
Seoul, Chongo-Gu, Yon-Gon Dong, Korea, Republic of, 110-744
Contact: Kyung-Sang Yu, M.D., Ph.D., M.B.A    +82-2-2072-1920    ksyu@snu.ac.kr   
Principal Investigator: Kyung-Sang Yu, M.D.,Ph.D.,M.B.A.         
Sub-Investigator: In-Jin Jang, M.D.,Ph.D.         
Sponsors and Collaborators
Dong-A Pharmaceutical Co., Ltd.
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: KEUMJAE KO / Assistant Manager, Clinical Development Team 1
ClinicalTrials.gov Identifier: NCT00961025     History of Changes
Other Study ID Numbers: DA1229_DM_I
First Posted: August 18, 2009    Key Record Dates
Last Update Posted: August 24, 2009
Last Verified: August 2009